Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

Phase 3 ODYSSEY MONO trial with alirocumab meets primary efficacy endpoint

Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the Phase 3 ODYSSEY MONO trial with alirocumab, an investigational monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9), met its primary efficacy endpoint.

16 Oct 2013

New injection device to reduce fear and pain of injecting modern medicines

...

15 Oct 2013

IBS Treatment Center opens new clinic in Santa Monica, California

The IBS Treatment Center, which specializes in treating irritable bowel syndrome, announced the opening of a new clinic in Santa Monica, California, in late October. Conveniently located next to the UCLA Medical Center, this new branch of the clinic will provide a progressive approach to digestive health as well as easy access to treatment for patients previously without adequate care.

15 Oct 2013

National autoimmune disease multi-city conference tour to arrive in Charleston, SC on November 2

A National autoimmune disease multi-city conference tour arrives in Charleston, SC on Saturday, November 2, 2013. The conference "What Every American Needs to Know About Autoimmune Disease," is one of a series of free patient forums hosted by the American Autoimmune Related Diseases Association.

15 Oct 2013

FDA approves OTREXUP injection for adults with RA, children with active pJIA

Antares Pharma, Inc. today announced the approval of OTREXUP (methotrexate) injection by the U.S. Food and Drug Administration. OTREXUP is the first FDA approved subcutaneous methotrexate for once weekly self-administration with an easy-to-use, single dose, disposable auto injector.

14 Oct 2013

Genentech plans to invest over $285M for expansion of biologics manufacturing facilities

Genentech, a member of the Roche Group, today announced plans to invest more than $285 million for the expansion of its biologics manufacturing facilities in Vacaville and Oceanside, California.

14 Oct 2013

Finding highlights new ways of treating inflammation disorders

A team led by scientists at The Scripps Research Institute (TSRI) has identified key signaling proteins in the inflammation process that contribute to the development of inflammatory diseases such as rheumatoid arthritis, psoriasis, sepsis and inflammatory bowel diseases.

11 Oct 2013

TSRI scientists identify set of compounds to treat multiple sclerosis in new way

Scientists at The Scripps Research Institute (TSRI) have identified a set of compounds that may be used to treat multiple sclerosis (MS) in a new way. Unlike existing MS therapies that suppress the immune system, the compounds boost a population of progenitor cells that can in turn repair MS-damaged nerve fibers.

10 Oct 2013

Compugen drug candidate prevents autoimmune type I diabetes in animal model

Compugen Ltd., announced today that CGEN-15001, an Fc fusion protein drug candidate derived from a novel immune checkpoint protein discovered by Compugen, has been shown to be highly efficient in preventing the development of disease in a well-accepted animal model of autoimmune type I diabetes, known also as juvenile diabetes.

9 Oct 2013

Anti-inflammatory mechanism leads to development of oral medications for atherosclerosis, IBS

Research led by Charles Nichols, PhD, Associate Professor of Pharmacology at LSU Health Sciences Center New Orleans, describes a powerful new anti-inflammatory mechanism that could lead to the development of new oral medications for atherosclerosis and inflammatory bowel disorders (IBS).

7 Oct 2013

Researchers identify protein that triggers inflammation in patients with hemorrhage, sepsis

Investigators at The Feinstein Institute for Medical Research have discovered a protein in the human body that can trigger and mediate inflammation in patients suffering from hemorrhage and sepsis. The findings were published in the online version of Nature Medicine on October 6, 2013.

7 Oct 2013

AbbVie announces HUMIRA phase II study results for treating hidradenitis suppurativa

AbbVie (NYSE: ABBV) today announced results from a post-hoc analysis of an investigational Phase II study, which evaluated HUMIRA® (adalimumab) in the treatment of patients with moderate-to-severe hidradenitis suppurativa (HS) after 16 weeks of therapy.

7 Oct 2013